To the Editor Using the National Cancer Data Base (NCDB) 2004 through 2012, Falchook and colleagues1 showed that while the adoption of dose-escalated radiation therapy (RT) for National Comprehensive Cancer Network intermediate- and high-risk prostate cancer increased to 90% of all external-beam RT recipients, the use of androgen deprivation therapy (ADT) was more heterogeneous, and influenced by geographic location of treating facility rather than patient comorbidity concerns. We noted that Charlson-Deyo comorbidity scores in the NCDB are categorized as 0, 1, and greater than 1 (not 2).2 More importantly, while we appreciate the findings noted by the authors, we wish to highlight some relevant areas of concern.
Dalela D, Karabon P, Abdollah F. Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate CancerSign of Changing Times?. JAMA Oncol. 2017;3(2):280-281. doi:10.1001/jamaoncol.2016.3987